BiotechTube
APIS Assay Technologies

APIS Assay Technologies

Cambridge, United Kingdom· Est.
apisassay.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.2M

Overview

APIS Assay Technologies is a commercial-stage diagnostics company with a dual business model of selling proprietary IVD kits and providing contract development services. Its core innovation is the Clickmer platform, a synthetic aptamer technology used to create high-affinity binding reagents for therapeutics, research, and diagnostics. The company has built a portfolio focused on oncology and pharmacogenomics, holds key ISO certifications, and operates with an integrated offering that includes assay development, bioinformatics, and regulatory support. APIS aims to translate biomarkers into clinical utility by helping diagnostics teams and biopharma companies accelerate from discovery to real-world impact.

OncologyPharmacogenomicsInfectious Disease

Technology Platform

Clickmer® system: chemically modified aptamers that form 3D structures to bind targets with high affinity and specificity, serving as synthetic antibody analogues for therapeutics, research, and diagnostics.

Funding History

1
Total raised:$1.2M
Seed$1.2M

Opportunities

The growing demand for personalized medicine and companion diagnostics in oncology provides a strong tailwind for its portfolio of mutation detection kits.
The contract development service line can capitalize on biopharma outsourcing trends, while the Clickmer platform has long-term potential to disrupt the large immunoassay and therapeutic antibody markets with a synthetic alternative.

Risk Factors

The company faces intense competition in molecular diagnostics from large, established players and newer NGS-based platforms.
Commercial scaling of its proprietary kits and the broader adoption of its novel Clickmer technology present significant execution challenges.
As a private company, it may have limited financial resources to fund simultaneous R&D, commercial expansion, and regulatory pathways.

Competitive Landscape

APIS competes in the molecular diagnostics space against global IVD giants (e.g., Roche, Qiagen, Abbott) offering broad PCR-based portfolios and large commercial teams. In niche areas like ESR1 testing, it faces competition from specialized liquid biopsy companies. Its Clickmer technology competes with traditional antibody suppliers and other aptamer developers, requiring clear differentiation on cost, performance, and scalability.

More companies in Diagnostics & Precision Medicine →More companies in United Kingdom →